SISB INVESTMENT ADVISERS (UK) LTD
Institutional investor · Portfolio as of Q2 2021
Top Holdings16 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
COUPANG INC | 568.2M | $23.8B | 46.6% | $48.75 | -13.52% | 2 qtrssince 2021-Q1 | Unchanged 0 |
DOORDASH INC - A | 55M | $9.8B | 19.2% | $140.20 | +31.18% | 3 qtrssince 2020-Q4 | Decreased 0 |
UBER TECHNOLOGIES INC | 129.1M | $6.5B | 12.7% | $46.38 | +9.44% | 9 qtrssince 2019-Q2 | Decreased 0 |
KE HOLDINGS INC-ADR | 81.2M | $3.9B | 7.6% | $53.87 | -68.72% | 2 qtrssince 2021-Q1 | Decreased 0 |
COMPASS INC | 132.4M | $1.7B | 3.4% | $13.50 | 0.00% | 1 qtr | New 91 |
OPENDOOR TECHNOLOGIES INC | 73.6M | $1.3B | 2.6% | $24.27 | -28.51% | 3 qtrssince 2020-Q4 | Unchanged 0 |
VIR BIOTECHNOLOGY INC | 22.6M | $1.1B | 2.1% | $12.12 | +284.16% | 7 qtrssince 2019-Q4 | Unchanged 0 |
ZYMERGEN INC | 26.6M | $1.1B | 2.1% | — | — | 1 qtr | New 86 |
RELAY THERAPEUTICS INC | 27.9M | $1B | 2.0% | $39.98 | -6.70% | 4 qtrssince 2020-Q3 | Unchanged 0 |
VIEW INC | 66.2M | $561.3M | 1.1% | — | — | 2 qtrssince 2021-Q1 | Unchanged 0 |
SEER INC | 5.1M | $168.3M | 0.3% | $50.72 | -96.00% | 3 qtrssince 2020-Q4 | Unchanged 0 |
Guardant Health, Inc. | 603,943 | $75M | 0.1% | $40.56 | +215.08% | 11 qtrssince 2018-Q4 | Decreased 0 |
ONECONNECT FINL TECHNOLOGY C | 4.3M | $51.8M | 0.1% | — | — | — | — |
DINGDONG CAYMAN LTD | 1.1M | $40.2M | 0.1% | $23.52 | -90.26% | 1 qtr | New 43 |
QUALTRICS INTL INC | 800,000 | $30.6M | 0.1% | — | — | 2 qtrssince 2021-Q1 | Unchanged 0 |
| 434,783 | $5.7M | 0.0% | — | — | 1 qtr | New 40 |
SB INVESTMENT ADVISERS (UK) LTD manages $51B across 16 positions as of Q2 2021. Top holdings: CPNG (46.6%), DASH (19.2%), UBER (12.7%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 2/5.0.
Added 4 new positions, trimmed 5. Top move: COMP (NEW, conviction 91). Portfolio: $51.0B across 16 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer